Abstract Number: 1537 • 2017 ACR/ARHP Annual Meeting
Determinants of Patient-Reported Improvement after Administration of Biological Treatment in Axial Spondyloarthritis: A Cross-Sectional Study
Background/Purpose: Efficacy of biological treatment in patients with axial spondyloarthritis (SpA) varies and is dependent on both disease-related and patient-related factors. The goal of this…Abstract Number: 1538 • 2017 ACR/ARHP Annual Meeting
Comparative Effectiveness of Early Versus Delayed Anti-TNF-α Treatment in Axial Spondyloarthritis
Background/Purpose: Anti-TNF-α agents are the mainstay of pharmacotherapy for patients with axial spondyloarthritis (AxSpA) who failed treatment with NSAIDs. A little is known about the…Abstract Number: 1539 • 2017 ACR/ARHP Annual Meeting
High Retention Rate and Sustained Responses with Secukinumab 150mg in Patients with Active Ankylosing Spondylitis: 3-Year Results from a Phase 3 Study
Background/Purpose: Secukinumab provided sustained improvement in the signs and symptoms of ankylosing spondylitis (AS) over 2 years in the MEASURE 2 study (NCT01649375).1,2 Here we…Abstract Number: 1540 • 2017 ACR/ARHP Annual Meeting
Comparison of Radiologic Parameters of Ankylosing Spondylitis Treated with Anti-TNF-α Versus Non-Steroidal Anti-Inflammatory Drugs and Sulfasalazine
Background/Purpose: There are many studies about impact of TNF-inhibitors on radiographic progression but little data are available on the relationship between treatment agents and sagittal…Abstract Number: 1541 • 2017 ACR/ARHP Annual Meeting
First Line Biological Treatment in Ankylosing Spondylitis, Prescription Rates, Baseline Demographics and Disease Activity. a Collaboration between Biological Registers in the Five Nordic Counties
Background/Purpose: Large-scale observational cohorts identified in national biological registries may be used to study effectiveness of biological disease modifying drugs (bDMARDs) in ankylosing spondylitis (AS).…Abstract Number: 1542 • 2017 ACR/ARHP Annual Meeting
Inequity in Biologic DMARD Prescription for Spa across the Globe: Results from the Multi-Centre, Cross-Sectional, ASAS Comospa Study
Background/Purpose: The value of biologic DMARDs (bDMARDs) in SpA is well recognized but global access to these treatments can be limited due to high cost…Abstract Number: 1543 • 2017 ACR/ARHP Annual Meeting
Real-World Effectiveness of TNF Inhibition in Spondyloarthritis. Data from a Large Nationwide Prospective Cohort – the British Society for Rheumatology Biologics Register for Ankylosing Spondylitis
Background/Purpose: TNF inhibition has revolutionised the treatment of axial spondyloarthritis (AxSpA). Much of what we know about the use of these drugs comes from randomised…Abstract Number: 1544 • 2017 ACR/ARHP Annual Meeting
The Effect of Extraarticular Manifestations on Tumor Necrotic Factor α Inhibitor Drug Survival in Patients with Ankylosing Spondylitis: Nationwide Data from the Korean College of Rheumatology Biologics (KOBIO) Registry
Background/Purpose: The tumor necrosis factor α inhibitor (TNFi) therapy has been shown to be remarkably effective in ankylosing spondylitis (AS). However, almost 30% of AS…Abstract Number: 1545 • 2017 ACR/ARHP Annual Meeting
Evaluation of the Adherence to Recommendations for Tnfα Blockers Use and Its Impact over 5 Years of Follow-up in Early Axial Spondyloarthritis. Data from the DESIR Cohort
Background/Purpose: Several recommendations have been published for the use of TNFα blockers (TNFb) in patients with axial Spondyloarthritis (axSpA). However, there is only sparse data…Abstract Number: 1546 • 2017 ACR/ARHP Annual Meeting
Comparative Effectiveness of Secukinumab and Golimumab in Ankylosing Spondylitis: Assessed By Matching-Adjusted Indirect Comparison Using Pivotal Phase 3 Clinical Trial Data
Background/Purpose: No data are available from head-to-head randomized controlled trials (RCTs) between secukinumab 150mg (SEC; an anti-IL-17A) and golimumab 50mg (GOL; a TNF inhibitor [TNFi])…Abstract Number: 1547 • 2017 ACR/ARHP Annual Meeting
Dose Tapering of TNFi in Patients with Axial Spondyloarthritis: An Observational Cohort Study from Nationwide Korean College of Rheumatology Biologic Registry (KOBIO)
Background/Purpose: To compare the clinical efficacy of dose-tapering strategy of tumor-necrosis factor inhibitor (TNFi) with that of standard-dose TNFi treatment in patients with spondyloarthritis (SpA)…Abstract Number: 1548 • 2017 ACR/ARHP Annual Meeting
Opioid Use in Patients with Ankylosing Spondylitis
Background/Purpose: The use or misuse of opioids has become a major public health issue in the USA. It is estimated that the economic burden of…Abstract Number: 1549 • 2017 ACR/ARHP Annual Meeting
A Non-Medical Switch from Originator Infliximab to Biosimilar CT-P13 in 36 Patients with Ankylosing Spondylitis: 6 – Months Clinical Outcomes from the Czech Biologic Registry Attra
Background/Purpose: A non-medical switch from originator (INX, Remicade) to biosimilar infliximab (CT-P13, Remsima) was conducted in 36 patients with ankylosing spondylitis (AS) in one clinical…Abstract Number: 1550 • 2017 ACR/ARHP Annual Meeting
One-Year Clinical Outcomes in 1623 Patients with Inflammatory Arthritis Who Switched from Originator to Biosimilar Etanercept – an Observational Study from the Danish Danbio Registry
Background/Purpose: According to Danish national guidelines issued in April 2016, a non-medical switch from originator (ETA, Enbrel) to biosimilar Etanercept (SB4, Benepali) (50 mg s.c.)…Abstract Number: 1551 • 2017 ACR/ARHP Annual Meeting
Avoidance of Physical Activity Leads to Reduced Inflammatory Enthesitis on Ultrasound
Background/Purpose: Enthesitis is one of the manifestations of psoriatic arthritis (PsA), but no clear definition for the diagnosis exists. To further evaluate the added value…
ACR Meeting Abstracts